# NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

> **NCT00675012** · PHASE2 · COMPLETED · sponsor: **AGC Biologics S.p.A.** · enrollment: 24 (actual)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** NGR-hTNF
- **DRUG:** Oxaliplatin
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT00675012
- **Lead sponsor:** AGC Biologics S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2010-12
- **Final completion:** 2013-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00675012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00675012, "NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00675012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*